Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study

No abstract is available for this paper.

• Publication year

  2003

• Venue

  International Journal of Cancer

• Publication date

  2003-07-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.11164PMID 12767075
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin

  2004cited by this paper
• Primary chemoprevention of familial adenomatous polyposis with sulindac.

  2002cited by this paper
• Primary chemoprevention of familial adenomatous polyposis with sulindac

  2002cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  2001cited by this paper
• Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2.

  2000cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• Cancer statistics, 2000

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate.

  2000cited by this paper
• Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.

  2000cited by this paper
• COX‐2 is expressed in human pulmonary, colonic, and mammary tumors

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Overexpression of cyclooxygenase-2 in carcinoma of the pancreas.

  1999cited by this paper
• Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

  1999cited by this paper
• Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.

  1999cited by this paper
• The relationship between cyclooxygenase-2 expression and colorectal cancer.

  1999cited by this paper
• Coordinate up‐regulation of low‐density lipoprotein receptor and cyclo‐oxygenase‐2 gene expression in human colorectal cells and in colorectal adenocarcinoma biopsies

  1999cited by this paper
• Clonogenic inactivation of colon cancer-derived cells treated with 5-fluorouracil and indomethacin in hybrid spheroids.

  1998cited by this paper
• Cyclooxygenase-2 inhibitors in tumorigenesis (Part II).

  1998cited by this paper
• Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.

  1998cited by this paper
• Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.

  1998cited by this paper
• Cyclooxygenase regulates angiogenesis induced by colon cancer cells.

  1998cited by this paper
• Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.

  1997cited by this paper
• Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.

  1997cited by this paper
• Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.

  1997cited by this paper
• Prostaglandin H synthases, nonsteroidal antiinflammatory drugs, and colon cancer

  1997cited by this paper
• Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2.

  1996cited by this paper
• Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma.

  1996cited by this paper
• Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.

  1995cited by this paper
• Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2.

  1995cited by this paper
• Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.

  1994cited by this paper
• Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.

  1994cited by this paper
• Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

  1993cited by this paper
• Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

  1993cited by this paper
• Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.

  1992cited by this paper
• Sulindac causes regression of rectal polyps in familial adenomatous polyposis.

  1991cited by this paper
• Cancer statistics

  1989cited by this paper
• Failure Patterns Following Curative Resection of Colonic Carcinoma

  1984cited by this paper
• Sulindac for polyposis of the colon

  1983cited by this paper
• Carcinoma of the colon and rectum: The natural history reviewed in 1704 patients

  1982cited by this paper

• LTβR-RelB signaling in intestinal epithelial cells protects from chemotherapy-induced mucosal damage

  2024cites this paper
• Formulation And In Vitro, In Vivo Evaluation of Colon Targeted Drug Delivery System Of 5-Fluorouracil

  2023cites this paper
• NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase

  2022cites this paper
• Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience.

  2021cites this paper
• Anticancer therapeutics: a brief account on wide refinements.

  2020cites this paper
• Cellular signaling pathways implicated in metastasis of colorectal cancer and the associated targeted agents.

  2015cites this paper
• Potency of non-steroidal anti-inflammatory drugs in chemotherapy (Review)

  2015cites this paper
• Potency of non-steroidal anti-inflammatory drugs in chemotherapy.

  2015cites this paper
• Predictive utility of cyclo-oxygenase-2 expression by colon and rectal cancer.

  2014cites this paper
• Synthesis, Anti-Inflammatory and Anti- Nociceptive Activities and Cytotoxic Effect of Novel Thiazolidin-4-ones Derivatives as Selective Cyclooxygenase (COX-2) Inhibitors

  2013cites this paper
• COX-2 as a molecular target of colon cancer chemoprevention: Promise and reality

  2012cites this paper
• Critical aspects in rationale design of fluorouracil-based adjuvant therapies for the management of colon cancer.

  2012cites this paper
• Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer

  2012cites this paper
• Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.

  2012cites this paper
• Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial

  2011cites this paper
• Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract

  2010cites this paper
• Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.

  2009cites this paper
• Cancer microenvironment and therapeutic implications

  2009cites this paper
• Colonic treatments and targets: issues and opportunities

  2009cites this paper
• New Indications for Established Drugs Able to Modify Tumour-Host Interactions

  2009cites this paper
• Antitumorale und antiangiogenetische Effekte von Biomodulatoren beim malignen Melanom und Angiosarkom

  2008cites this paper
• Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy

  2008cites this paper
• The anti-proliferative potency of celecoxib is not a class effect of coxibs.

  2008cites this paper
• The effects of Nimesulide combined with cisplatin on lung cancer

  2008cites this paper
• Cancer, cyclo-oxygenase and nonsteroidal anti-inflammatory drugs - can we combine all three?

  2007cites this paper
• Treating cancer with NSAIDs. Reality or optimism?: Part 1

  2007cites this paper
• Synergistic antitumor effects of celecoxib with 5‐fluorouracil depend on IFN‐γ

  2007cites this paper
• Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic.

  2007cites this paper
• Reversal of doxorubicin resistance by adenovirus- mediated transfer of cyclooxygenase-2 antisense in multidrug-resistant MCF-7 cells

  2007influential citation
• Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.

  2007cites this paper
• 5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage

  2007cites this paper
• Cyclooxygenase-2 as a target for anticancer drug development.

  2006cites this paper
• The role of COX-2 in chemoprevention of colorectal cancer: A friend or an enemy?

  2006cites this paper
• Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs.

  2006cites this paper
• Retrospective Study of Capecitabine and Celecoxib In Metastatic Colorectal Cancer: Potential Benefits and COX-2 as the Common Mediator in Pain, Toxicities and Survival?

  2006cites this paper
• Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.

  2006cites this paper
• Cervix A PHASE II STUDY OF ACUTE TOXICITY FOR CELEBREX TM ( CELECOXIB ) AND CHEMORADIATION IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER : PRIMARY ENDPOINT ANALYSIS OF RTOG 0128

  2006cites this paper
• FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).

  2006cites this paper
• Cyclooxygenase‑2: A Potential Target in the Treatment of Oral Cancers

  2005cites this paper
• Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer

  2005cites this paper
• Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?

  2005cites this paper
• Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae.

  2005cites this paper
• New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy.

  2005cites this paper
• Whither irinotecan?

  2005cites this paper
• A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.

  2005cites this paper
• Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract.

  2005cites this paper
• Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases.

  2005cites this paper
• Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.

  2005cites this paper
• A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.

  2005cites this paper
• Cancer Prevention: A New Era beyond Cyclooxygenase-2

  2005cites this paper
• Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat.

  2005cites this paper
• Control of cancers by combining antiangiogenesis and cancer immunotherapy.

  2005cites this paper
• COX-2: a molecular target for colorectal cancer prevention.

  2005cites this paper
• Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat

  2005cites this paper
• Cyclooxygenase-2 inhibition in colon experimental carcinogenesis

  2005cites this paper
• Caveolae Signaling Complex Components into Ceramide-Enriched Clustering of DR 5 and Concentrating Death-Inducing Carcinoma Cells to TRAIL-Induced Apoptosis through Cyclooxygenase-2 Inhibition Sensitizes Human Colon

  2005cites this paper
• Influence of rofecoxib on experimental colonic carcinogenesis in rats

  2004cites this paper
• Cyclooxygenase-2 Expression : A Significant Prognostic Indicator for Patients With Colorectal Cancer Labile

  2004cites this paper
• Keuntungan Sediaan ?Preferential COX-2 Inhibitor? Dalam Penanggulangan Nyeri Kanker

  2004cites this paper
• Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells

  2004cites this paper
• Cyclooxygenase activity in gastrointestinal cancer development and progression: prospects as a therapeutic target

  2004cites this paper
• Cancer and Inflammation

  2004cites this paper
• Cyclooxygenase-2 Expression

  2004cites this paper
• Influence of rofecoxib on experimental colonic carcinogenesis in rats.

  2004cites this paper
• Cyclooxygenase-2 and its role in colorectal cancer development

  2004cites this paper
• Dose of rofecoxib in colorectal cancer

  2004cites this paper
• Cyclooxygenase in the treatment of glioma: its complex role in signal transduction.

  2004cites this paper
• The status of chemoprevention in the current cancer therapeutic armamentarium.

  2004cites this paper
• Dose of rofecoxib in colorectal cancer

  2004cites this paper
• Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

  2004cites this paper
• COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet?

  2004cites this paper
• Induction of cyclooxygenase-1 in cultured synovial cells isolated from rheumatoid arthritis patients

  2004cites this paper
• International Conference on Health Care and Management “ Evidence to inform action on supporting and implementation of SDGs ”

  year unknowncites this paper
• Chemoprevention of colorectal cancer

  year unknowncites this paper